Bristol wins approval of Camzyos for children with rare heart condition (BMY:NYSE)

Bristol Myers Squibb announced FDA approval for Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients over 66 pounds. The company claims it is the only FDA-approved treatment for pediatric patients with this condition, addressing a significant unmet need. Bristol Myers Squibb is also discussing pediatric data with global regulators for potential further indications.

The FDA approved Bristol Myers Squibb's mavacamten (Camzyos) for pediatric patients with obstructive hypertrophic cardiomyopathy (oHCM), expanding its use to those weighing at least 30 kg. The approval follows positive results from the SCOUT-HCM trial, which showed significant reduction in LVOT gradient. Bristol Myers Squibb states it is the only FDA-approved therapy for oHCM in pediatric patients.

Bristol Myers Squibb (BMY) announced FDA approval of CAMZYOS (mavacamten) for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and pediatric patients weighing 30 kg or more. The approval is based on positive Phase 3 SCOUT-HCM trial results, showing significant reduction in Valsalva LVOT gradient. CAMZYOS now has the broadest indication among cardiac myosin inhibitors.

The FDA approved Bristol Myers Squibb's CAMZYOS for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in pediatric patients weighing 30 kg or more. The approval follows positive Phase 3 SCOUT-HCM trial results, showing significant reductions in Valsalva left ventricular outflow tract (LVOT) gradient compared to placebo. CAMZYOS is the only FDA-approved therapy for pediatric oHCM, expanding its existing approval for adults.

Bristol Myers Squibb (BMY) received FDA approval for Camzyos to treat pediatric obstructive hypertrophic cardiomyopathy. The company offers a 3.93% dividend yield with a 41% payout ratio and a GF Score of 73. BMY's stock is trading 10.2% above its GF Value of $56.65, indicating fair valuation. The approval strengthens BMY's cardiovascular portfolio.

Bristol Myers Squibb's Camzyos (mavacamten) received FDA approval for children with symptomatic obstructive hypertrophic cardiomyopathy. The approval follows positive phase 3 trial results showing reduced left ventricular outflow tract pressure. The drug carries a heart failure risk warning and is restricted through a REMS program.